NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

FDA Grants Breakthrough Status to Vision-Saving Drug for Optic Neuritis

Oculis (OCS) receives FDA Breakthrough Therapy Designation for Privosegtor, a promising treatment that could become the first neuroprotective therapy for optic neuritis and related eye conditions.

FDA Grants Breakthrough Status to Vision-Saving Drug for Optic Neuritis
Credit: Oculis
Already have an account? Sign in.
01/06/2026 · 10:49 AM
OCS
/ Don’t stop at just one post.

Related↓

Oculis DIAMOND Trial Results: Vision Goal Not Met, But Retina Improved – Company Shifts Focus
05/29/2026 · 4:17 PM

Oculis DIAMOND Trial Results: Vision Goal Not Met, But Retina Improved – Company Shifts Focus

Oculis eye drops failed main vision goal in DME trials but reduced swelling; no FDA filing, company shifts focus, strong cash until 2029.

/ Subscriber only
/ Read more

Feed↓

Evolus shares fall after FDA calls Jeuveau Instagram post misleading
10/02/2026 · 4:04 PM

Evolus shares fall after FDA calls Jeuveau Instagram post misleading

The FDA says an Evolus Instagram post overstated Jeuveau benefits and downplayed risks. The firm has 15 working days to respond.

/ Subscriber only
Novartis licenses Abogen’s mRNA autoimmune drug in deal worth up to $7.8 billion
Featured/ 10/02/2026 · 3:45 PM

Novartis licenses Abogen’s mRNA autoimmune drug in deal worth up to $7.8 billion

Novartis will pay $575 million upfront for worldwide rights to Abogen's mRNA T-cell engager, plus up to $7.2 billion in milestones.

/ Subscriber only
20 New Planet Satellites Reach Orbit on SpaceX’s Transporter-18
10/02/2026 · 2:42 PM

20 New Planet Satellites Reach Orbit on SpaceX’s Transporter-18

Planet Labs put 20 satellites in orbit on Oct. 1, 2026, including a Google TPU prototype, Tanager-2 methane sensor, and 18 SuperDoves.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe